---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-109479"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:42:01.864999+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD posts Q3 net income of $50K vs year-ago loss; license revenue up 43%

## Summary
- Net income from continuing operations was $50K ($0.00 per share) vs net loss of $567K ($0.05) in Q3 2024.
- License revenue from Mayne Agreement rose 43% to $784K from $547K year-over-year.
- Total operating expenses decreased 2.1% to $1,646K, roughly flat from prior year.
- Company evaluating strategic alternatives including M&A, sale of assets; no timetable set.
- Cash and cash equivalents stood at $7.1 million as of September 30, 2025.

## SEC filing metadata
- accession: 0001213900-25-109479
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000121390025109479/0001213900-25-109479-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000121390025109479/ea0265416-8k_therape.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-109479
- JSON: https://secwatch.observer/filing/0001213900-25-109479.json
- Plain text: https://secwatch.observer/filing/0001213900-25-109479.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.